Description
A prodrug form of brivanib; reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis at 3 mg/kg per day; reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition at 107 mg/kg
Formal name: L-alanine, (1R)-2-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-1-methylethyl ester
Synonyms: BMS 582664
Molecular weight: 441.5
CAS: 649735-63-7
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|FGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Toxicology|Drug Metabolism